Neurocrine Biosciences
NBIX
#1366
Rank
NZ$26.83 B
Marketcap
NZ$269.19
Share price
0.84%
Change (1 day)
25.25%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2025 : NZ$0.74 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is NZ$0.74 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31NZ$0.80 B19.12%
2023-12-31NZ$0.67 B63.6%
2022-12-31NZ$0.41 B-35.78%
2021-12-31NZ$0.64 B12.84%
2020-12-31NZ$0.57 B-22.33%
2019-12-31NZ$0.73 B27.03%
2018-12-31NZ$0.57 B11.29%
2017-12-31NZ$0.52 B
2009-12-31NZ$15.87 M-40.17%
2008-12-31NZ$26.53 M1267.65%
2007-12-31NZ$1.93 M-97.45%
2006-12-31NZ$76.14 M-12.39%
2005-12-31NZ$86.91 M-6.22%
2004-12-31NZ$92.67 M65.35%
2003-12-31NZ$56.04 M269.65%
2002-12-31NZ$15.16 M10.71%
2001-12-31NZ$13.69 M56.82%
2000-12-31NZ$8.73 M47.22%
1999-12-31NZ$5.93 M4.2%
1998-12-31NZ$5.69 M106.46%
1997-12-31NZ$2.75 M21.75%
1996-12-31NZ$2.26 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
NZ$1.19 B 60.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$15.48 B 1,988.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
NZ$0.45 M-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$73.57 B 9,822.18%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$118.99 B 15,946.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$105.32 B 14,103.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$1.07 B 44.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$32.15 M-95.66%๐Ÿ‡บ๐Ÿ‡ธ USA